SLC5A2 and Stroke: Based on the eligibility criteria in our study, data from RCTs involving SGLT2 inhibitors that reported total stroke events or its subtypes (including fatal, non-fatal, ischemic, hemorrhagic or TIA) as primary endpoints or safety were selected for further meta-analysis.